KEAP1 and cancer: Given that BRD4 is frequently elevated in cancer cells compared to normal cells, co-targeting of BRD4 and the KEAP1-Nrf2-G6PD axis might not only maximize the clinical efficacy of BET inhibitors but also cause fewer side effects in patients.